Cardiovascular Outcomes Reported in Hemodialysis Trials.

[1]  P. Tugwell,et al.  Core Outcome Set–STAndards for Reporting: The COS-STAR Statement , 2016, PLoS medicine.

[2]  David W. Johnson,et al.  Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  D. Altman,et al.  Improving the relevance and consistency of outcomes in comparative effectiveness research. , 2016, Journal of comparative effectiveness research.

[4]  Connie M. Rhee,et al.  US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  R. Autschbach,et al.  A core outcome set for all types of cardiac surgery effectiveness trials: a study protocol for an international eDelphi survey to achieve consensus on what to measure and the subsequent selection of measurement instruments , 2015, Trials.

[6]  David W. Johnson,et al.  Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis , 2015, Trials.

[7]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[8]  G. Perkins,et al.  A systematic review of the outcomes reported in cardiac arrest clinical trials: the need for a core outcome set. , 2015, Resuscitation.

[9]  C. Terwee,et al.  Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a ‘core outcome set’ , 2014, Trials.

[10]  Harlan M Krumholz,et al.  Increasing value and reducing waste: addressing inaccessible research , 2014, The Lancet.

[11]  R. Tibshirani,et al.  Increasing value and reducing waste in research design, conduct, and analysis , 2014, The Lancet.

[12]  A. Martínez‐Castelao,et al.  High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. , 2013, Journal of the American Society of Nephrology : JASN.

[13]  Nick Black,et al.  Patient reported outcome measures could help transform healthcare , 2013, BMJ.

[14]  K. Mahaffey,et al.  Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. , 2012, The New England journal of medicine.

[15]  Jane M Blazeby,et al.  Developing core outcome sets for clinical trials: issues to consider , 2012, Trials.

[16]  P. Williamson,et al.  Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people , 2012, Trials.

[17]  M. Bots,et al.  Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. , 2012, Journal of the American Society of Nephrology : JASN.

[18]  V. Montori,et al.  The idolatry of the surrogate , 2011, BMJ : British Medical Journal.

[19]  G. Remuzzi,et al.  The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. , 2011, Kidney international.

[20]  Paul Heidenreich,et al.  ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards , 2011, Circulation.

[21]  R. Hendel,et al.  ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. , 2011, Journal of the American College of Cardiology.

[22]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[23]  Nicholas C. Ide,et al.  The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.

[24]  U. Patel.  Faculty Opinions recommendation of In-center hemodialysis six times per week versus three times per week. , 2010 .

[25]  G. Beck,et al.  In-center hemodialysis six times per week versus three times per week. , 2010, The New England journal of medicine.

[26]  H. Kölsch,et al.  Reporting bias in medical research - a narrative review , 2010, Trials.

[27]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[28]  Kevin E. Kip,et al.  The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. , 2008, Journal of the American College of Cardiology.

[29]  P. Tugwell,et al.  OMERACT: An international initiative to improve outcome measurement in rheumatology , 2007, Trials.

[30]  G. Guyatt,et al.  Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. , 2007, Journal of clinical epidemiology.

[31]  Gordon H Guyatt,et al.  Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.

[32]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[33]  J. Aronson.  Biomarkers and surrogate endpoints. , 2005, British journal of clinical pharmacology.

[34]  M. Rocco,et al.  Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. , 2004, Kidney international.

[35]  R. Foley,et al.  Epidemiology of cardiovascular disease in chronic renal disease , 2000 .

[36]  R. Petersen,et al.  Clinical Subtypes of Alzheimer’s Disease , 1998, Dementia and Geriatric Cognitive Disorders.

[37]  P. Serruys,et al.  Usefulness of quantitative and qualitative angiographic lesion morphology, and clinical characteristics in predicting major adverse cardiac events during and after native coronary balloon angioplasty. CARPORT and MERCATOR Study Groups. , 1993, The American journal of cardiology.

[38]  Theresa Schilhab,et al.  Issues to Consider , 2017 .

[39]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Journal of the American College of Cardiology.

[40]  Hugh Calkins,et al.  ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). , 2006, Circulation.

[41]  David C. Murray,et al.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. , 1995, Kidney international.